Arrowhead's REDEMPLO Gains EU Approval for Rare Triglyceride Disorder

Event summary

  • European Commission grants marketing authorization for REDEMPLO® (plozasiran) to treat familial chylomicronemia syndrome (FCS).
  • First siRNA medicine approved in EU for FCS, applicable to both clinically diagnosed and genetically confirmed patients.
  • Phase 3 PALISADE study showed 80% triglyceride reduction vs. 17% with placebo; 83% lower odds of acute pancreatitis.
  • REDEMPLO is self-administered via subcutaneous injection every three months.

The big picture

Arrowhead's EU approval for REDEMPLO solidifies its position in the rare disease space, particularly in treating FCS with a novel siRNA approach. The ability to treat without genetic confirmation addresses a significant unmet need and could accelerate patient access. This approval follows prior authorizations in the U.S., Canada, China, and Australia, reflecting the global potential of Arrowhead's TRiM™ platform technology.

What we're watching

Market Expansion
How quickly Arrowhead can secure national approvals and healthcare community adoption across the EU.
Pipeline Progress
The pace at which plozasiran advances in other indications like severe hypertriglyceridemia through ongoing Phase 3 studies.
Competitive Positioning
Whether Arrowhead can sustain its lead as the only siRNA treatment approved for both clinically diagnosed and genetically confirmed FCS patients.